Home » Value, Access, and Pricing

Thought Leadership

CBPartners’ Value, Access, and Pricing teams are composed of the industry’s leading thought leaders and seasoned engagement managers who work relentlessly to support client value, access, and pricing.

Showing 5 of 30 posts
Non-traditional Players Attempting Healthcare PART I
September 8, 2021 | Blogs

Part I: Non-Traditional Players Attempting Entry Into the Healthcare Sector

In part one of this two-part series about non-traditional players in the healthcare sector, CBPartners explores the increasingly attractive market despite the risk of an expensive failed venture by analyzing the success and failures of four non-traditional players.

September 1, 2021 | Blogs

Exploring the Impact of COVID-Driven Trends on the US Healthcare Landscape

CBPartners reviews the COVID-driven changes to patients, providers, payers, clinical research, and pharmaceutical distribution within the US.

Oncology Market Access Opportunities 2020 NRDL
August 26, 2021 | Blogs

What Market Access Opportunities Exist for Oncology Products in China? An Analysis of Oncology Product Inclusion in the 2020 NRDL

Fourteen oncology drugs were successfully negotiated and included in the 2020 NRDL. As the new prices became effective from March 01, 2021, several key features and trends have been observed.

Regulators and HTA Bodies
August 24, 2021 | Blogs, Infographics

Drug Assessment Uncertainties: HTA Bodies vs. Regulators

A recent study of the review of new medicines by regulatory and HTA bodies has revealed areas of misalignment in their processes, highlighting unique challenges in the pathway to patient access.

Cover Image for NRDL Market Access Rare Disease Therapies China 2020 NRDL
August 19, 2021 | Blogs

What Market Access Opportunities Exist for Rare Disease Products in China? An Analysis of Rare Disease Product Inclusion in the 2020 NRDL

The first of two articles investigating market access opportunities in China - CBPartners’ Asia-Pacific Center of Excellence analyzes the opportunities that lie ahead for rare disease products based on 2020 NRDL update inclusion.